Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Daiichi Sankyo : Announces Positive Results from ESAX-DN Phase 3 study in Japan of Esaxerenone in Patients with Diabetic Nephropathy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2019 | 08:15am EST

Tokyo - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the primary objective has been achieved from ESAX-DN, a Phase 3 pivotal study of esaxerenone, a non-steroidal, selective novel mineralocorticoid receptor (MR) blocker, for patients in Japan with diabetic nephropathy.

The ESAX-DN results were presented in a late-breaking presentation during Kidney Week 2019, the annual meeting of the American Society of Nephrology, in Washington, USA.

ESAX-DN is a phase 3 randomized, double-blind, 2-arm, parallel group comparison study with placebo in incipient diabetic nephropathy patients1 who are taking an angiotensin II receptor blocker (ARB) or an angiotensin converting enzyme (ACE) inhibitor in Japan.

The study showed the esaxerenone-based regimen had a significantly higher Urine Albumin-to-Creatinine Ratio (UACR) remission2 rate (esaxerenone: 22.1% vs. placebo: 4.0%) and significantly reduced UACR (esaxerenone:-58.3% vs. placebo: 8.3) compared with the placebo group. As the secondary endpoint, significant reduction of progression from incipient to overt diabetic nephropathy3 (esaxerenone: 1.4%vs. placebo: 7.5%) was confirmed in the esaxerenone group compared to the placebo group.

Additionally, no new safety concerns were identified in this study. 8.8% of confirmed hyperkalemia was observed in the esaxerenone group compared with 2.2% in the placebo group, and elevated serum potassium was recovered after discontinuation of administration.

Daiichi Sankyo will further contribute to medical care by using the scientific knowledge around esaxerenone, which has been expanded through the ESAX-DN study results.

Incipient diabetic nephropathy means type 2 diabetes with microalbuminuria, which is defined 45UACR300 mg/gCr in this study.

Satisfying both reversal to normal range of UACR, which is an index of kidney function, and sustainment; defined as achieving two consecutive UACR

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
11/11DAIICHI SANKYO : Announces Positive Results from ESAX-DN Phase 3 study in Japan ..
AQ
11/06DAIICHI SANKYO : Files Declaratory Judgement Action Related to its Proprietary A..
AQ
10/16DAIICHI SANKYO : Announces Transfer from Astellas Pharma of Three Products in As..
AQ
09/27Kansai Electric president apologises for payments scandal
RE
09/27DAIICHI SANKYO COMPANY, LIMITED : Ex-dividend day for interim dividend
FA
09/18Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatme..
AQ
09/17Trial of Tepco executives over Japan's Fukushima disaster heads to conclusion
RE
09/12DAIICHI SANKYO : Announces Launch of Oxycodone Extended Release Tablets NX 'Daii..
AQ
09/04AstraZeneca's Tagrisso gets China OK for type of lung cancer
RE
08/23GSK builds oncology pipeline as drug shown to help myeloma patients
RE
More news
Financials (JPY)
Sales 2020 972 B
EBIT 2020 134 B
Net income 2020 100 B
Finance 2020 603 B
Yield 2020 1,02%
P/E ratio 2020 44,5x
P/E ratio 2021 52,7x
EV / Sales2020 3,97x
EV / Sales2021 4,12x
Capitalization 4 458 B
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 7 825,00  JPY
Last Close Price 6 880,00  JPY
Spread / Highest target 45,3%
Spread / Average Target 13,7%
Spread / Lowest Target -20,1%
EPS Revisions
Managers
NameTitle
Sunao Manabe President, CEO & Representative Director
Joji Nakayama Chairman
Toshiaki Sai CFO, Representative Director & Executive VP
Wataru Takasaki Executive Officer, GM-Research & Development
Toshiaki Tojo Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED95.59%40 879
JOHNSON & JOHNSON3.06%344 670
ROCHE HOLDING AG22.19%254 722
MERCK AND COMPANY8.99%211 953
PFIZER-15.40%208 023
NOVARTIS17.78%198 320